ASH 2023 | Ibrutinib & chemotherapy (TEDDI-R) in the treatment of secondary CNS lymphoma
Mark Roschewski
• 8 Dec 2023
Mark Roschewski, MD, National Cancer Institute, Bethesda, MD, introduces a Phase II trial (NCT03964090) investigating the efficacy of ibrutinib with temozolomide, etoposide, liposomal doxorubicin, dexamethasone, and rituximab (TEDDI-R) to treat patients with secondary CNS lymphoma. The data indicates that durable responses are achieved in the subset of patients who respond to ibrutinib, as assessed in preliminary testing. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
